One Stop Shop for All Your Market Research Reports

Global Liquid Biopsy Market by Sample Type (Blood, Urine and Others), by Biomarker Type (CTC, Ctdna and Others), By Application (Lung Cancer, GIT Cancer, Breast, Colorectal, Lukemia, Prostate and Others), By End User Type (Hospitals, Academic Institutes, Diagnostic Labs and Cancer Research Centers) and by Region (North America, Latin America, Europe, APAC and MEA) - Size, Share, Growth, Trends, and Forecasts (2016–2024)

The global liquid biopsy market has been estimated at USD 418.5 in 2016 and is projected to reach USD 2,112.3 million by 2024, at a CAGR of 22.5% during the forecast period from 2016 to 2024. Liquid biopsy is a cutting-edge non-invasive cancer diagnosis process which uses biofluids such as blood, urine, plasma, cerebrospinal fluid (CSF) for detecting various cancers. The liquid biopsy test is useful for identifying cancer in early stages. The liquid biopsy test uses various biomarkers such as circulating tumour cells (CTC), circulating nucleic acids and exosomes as a biomarker for diagnosis of cancer. In the patient body, above-mentioned biomarkers can be released in to body fluids by cancer cells. Among all samples, blood sample is extensively used for diagnosis of various cancers such as lung cancer, GIT cancer, breast cancer, and leukemia. Urine and cerebrospinal samples are mainly used for detection of prostate and brain cancers respectively. Market Dynamics: Major drivers in the global liquid biopsy market are increasing prevalence of various cancers such as lung cancer, breast cancer, GIT cancers and prostate cancers and rising accessibility of advanced diagnosis procedures. These factors are expected to drive growth of the global liquid biopsy market during the forecast period. Other prominent driving factors are increasing oncologists preference towards liquid biopsy procedure for detecting cancer and increasing number of biotechnology and pharmaceutical companies research and developments to discover anti-cancer drugs.  In addition to this, increasing regulatory bodies’ approvals for various new non-invasive tests is also driving growth of global liquid biopsy market. However, high cost, reimbursement scenario and awareness are the major restraining factors are expecting to hamper global liquid biopsy market over the forecast period. By sample type, the global liquid biopsy market has been segment into blood, urine, and others (saliva, plasma, Cerebrospinal fluid (CSF)). By marker type, the global liquid biopsy market has been segment into circulating tumour Cells (CTCs), circulating tumour nucleic acids (ctNA), and exosomes. By disease indication, the global liquid biopsy market has been segmented into lung cancer, gastrointestinal cancer (GIT), breast cancer, colorectal, prostate cancer, leukemia and others. In terms of value, Lung cancer disease indication segment is currently accounts for utmost revenue as compared to other disease indication segments in the global liquid biopsy market. While breast cancer and colorectal cancers disease indication segments are anticipated to contribute significant revenue in global liquid biopsy market by the end of 2024. By end user, the global liquid biopsy market has been segmented into hospitals, cancer institutes, academic institutes and diagnostic centres. In terms of value, Cancer institute end user segment is expected to make significant incremental opportunity in global liquid biopsy market over the forecast period. The global liquid biopsy market has been segmented into five major regions: North America, Latin America, Europe, Europe, APAC, and Middle East & Africa (MEA). In 2016, North America is expected to account for the largest share and is expected to register a CAGR of 20.9% over the forecast period. This is owing to high adoption of novel advanced diagnostic technologies as well as increasing cancer prevalence in the U.S. and Canada. In terms of value, APAC region is estimated to be the fastest growing market and is expected to register a CAGR of 24.3% over the forecast period. By disease indication segment, Lung cancer disease segment in the APAC liquid biopsy market is expected to register a CAGR of 21.8% over the forecast period, owing to increasing lung cancer prevalence in this region. Major players in the global liquid biopsy market are BIOCEPT, INC., F. Hoffmann-La Roche Ltd., Qiagen N.V., Inc., Janssen Global Services, LLC,  MDxHealth SA, Natera, Inc., Silicon Biosystems, Sysmex Corporation, Trovagene, and Pathway Genomics Corporation.

Table of Content

1. Executive Summary 2. Assumptions and Acronyms 3. Research Methodology 4. Liquid Biopsy Market Overview 4.1. Liquid Biopsy Market Introduction 4.1.1. Market Definition 4.1.2. Market Taxonomy 4.2. Liquid Biopsy Market Dynamics (DROT) 4.2.1. Market Drivers 4.2.2. Market Restraints 4.2.3. Market Opportunities 4.2.4. Market Restraints 4.3. Pipeline Assessment, By Products 4.4. Product Penetration and Pricing Impact 5. Global Liquid Biopsy Market Forecast and Analysis, By Sample Type 5.1. Introduction 5.2. By Sample Type 5.2.1. Blood 5.2.2. Urine 5.2.3. Others (Plasma, Saliva, CSF) 6. Global Liquid Biopsy Market Forecast and Analysis, By Marker Type 6.1. Introduction 6.2. By Marker Type 6.2.1. CTCs (circulating tumor cells) 6.2.2. ctNA (circulating tumor nucleic acids) 6.2.3. Exosomes 7. Global Liquid Biopsy Market Forecast and Analysis, By End User 7.1. Introduction 7.2. By End User 7.2.1. Hospitals 7.2.2. Academic Institutes 7.2.3. Cancer Institutes 7.2.4. Diagnostic Centers 7.3. Market Attractiveness Analysis, By End User
Inquiry Before Buying
Request Sample
To choose the report type and your desired payment method

Share This Report

Our Clients

Latest Market News

Total – Maersk Deal Sees Total Buying Maersk Oil Business

A Total - Maersk deal has led to Total buying the Maersk oil operation for $7.45 Billion (£5.8 bn).  Maersk Oil is a Danish company that has the concession for the exploration and production of oil and gas in the Danish sector of the North Sea.  By purchasing Maersk, the French oil giant Total has suddenly become th [...]

Read More
BHP Billiton Shale Assets to be Sold Through Elliot Management Pressure

BHP Billiton US shale assets in the US are to be sold. The decision was made after the Australian mining company declared a net profit of $5.89 billion. Although this result was lower than analysts expected it was still better than last year. The global mining firm made a record loss in 20176 of $6.39 billion.   [...]

Read More
US Car Production and the Japanese Syndrome

US car production is gradually slowing down.  Ford SUV sales in July 2017 have increased by 2.2% over July, 2016. However, overall auto sales were down 7.4% for the same July. How is this, and what can be done to ensure non-SUV sales maintain a high position in the market?   The so-called ‘Japanese syndro [...]

Read More
US Factory Output Drops in July Through Falling Car Production

US factory output dropped in July according to the Federal Reserve.  The main reason for this was ascribed to falling car production. While factory output dropped by 0.1%, overall production increased by 0.2%.  This figure includes mining and utilities, increasing by 0.5% and 1.6% respectively.   This info [...]

Read More
US-China Trade Relationship in Jeopardy Through Trump’s Actions

Further to our recent news article “Is the US-China Trade Relationship in Jeopardy?” the US has now launched an official investigation into China’s use of ‘intellectual property.’ The US-China Trade Relationship appears to be in trouble regarding China’s use of counterfeit goods and pirated software. &nb [...]

Read More
Payment Mode
Single User $ 4575
Multi User $6575
Corporate User $8575
About this Report
Report ID 22379
Category
  • Medical Devices
  • Pharmaceuticals and Healthcare
Published on Upcoming
Number of Pages 200
Publisher Name Upcoming Reports
Over all Rating
"Rating is based on 689 reviews"